Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients

The objective of this study was to examine the maintenance of effect and safety after a hospital‐wide switch for economic reasons from adalimumab originator Humira® to biosimilar Amgevita® in real‐world rheumatoid arthritis (RA) patients and patient satisfaction with the switch. We conducted a singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwer, Rianne, ten Klooster, Peter M., Masselink, Joost B., Vonkeman, Harald E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731312/
https://www.ncbi.nlm.nih.gov/pubmed/36479936
http://dx.doi.org/10.1002/prp2.1025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731312/
https://www.ncbi.nlm.nih.gov/pubmed/36479936
http://dx.doi.org/10.1002/prp2.1025

Ejemplares similares